As of 2024-07-27, the Relative Valuation of Myriad Genetics Inc (MYGN) is (78.93) USD. This relative valuation is based on P/E multiples. With the latest stock price at 27.65 USD, the upside of Myriad Genetics Inc based on Relative Valuation is -385.4%.
The range of the Relative Valuation is (79.42) - (80.30) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 30.6x - 31.6x | 30.8x |
| Forward P/E multiples | 25.9x - 31.0x | 30.1x |
| Fair Price | (79.42) - (80.30) | (78.93) |
| Upside | -387.2% - -390.4% | -385.4% |
| Date | P/E |
| 2024-07-26 | -10.67 |
| 2024-07-25 | -10.74 |
| 2024-07-24 | -10.81 |
| 2024-07-23 | -10.81 |
| 2024-07-22 | -10.71 |
| 2024-07-19 | -10.02 |
| 2024-07-18 | -10.27 |
| 2024-07-17 | -10.45 |
| 2024-07-16 | -10.57 |
| 2024-07-15 | -10.28 |
| 2024-07-12 | -10.19 |
| 2024-07-11 | -9.99 |
| 2024-07-10 | -9.70 |
| 2024-07-09 | -9.74 |
| 2024-07-08 | -9.75 |
| 2024-07-05 | -9.61 |
| 2024-07-03 | -9.63 |
| 2024-07-02 | -9.55 |
| 2024-07-01 | -9.25 |
| 2024-06-28 | -9.44 |
| 2024-06-27 | -9.38 |
| 2024-06-26 | -9.50 |
| 2024-06-25 | -9.51 |
| 2024-06-24 | -9.46 |
| 2024-06-21 | -9.36 |
| 2024-06-20 | -9.18 |
| 2024-06-18 | -9.22 |
| 2024-06-17 | -9.27 |
| 2024-06-14 | -8.95 |
| 2024-06-13 | -8.99 |
| 2024-06-12 | -9.09 |
| 2024-06-11 | -8.67 |
| 2024-06-10 | -8.56 |
| 2024-06-07 | -8.54 |
| 2024-06-06 | -8.60 |
| 2024-06-05 | -8.76 |
| 2024-06-04 | -8.62 |
| 2024-06-03 | -8.62 |
| 2024-05-31 | -8.78 |
| 2024-05-30 | -8.67 |
| 2024-05-29 | -8.76 |
| 2024-05-28 | -9.00 |
| 2024-05-24 | -8.94 |
| 2024-05-23 | -8.98 |
| 2024-05-22 | -9.26 |
| 2024-05-21 | -9.41 |
| 2024-05-20 | -9.65 |
| 2024-05-17 | -9.76 |
| 2024-05-16 | -9.49 |
| 2024-05-15 | -9.51 |